181 related articles for article (PubMed ID: 19563407)
1. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
Brustmann H; Naudé S
Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
[TBL] [Abstract][Full Text] [Related]
3. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
5. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
6. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
7. Expression of Fas and FasL in human serous ovarian epithelial tumors.
van Haaften-Day C; Russell P; Davies S; King NJ; Tattersall MH
Hum Pathol; 2003 Jan; 34(1):74-9. PubMed ID: 12605369
[TBL] [Abstract][Full Text] [Related]
8. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
9. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.
Kauppila S; Saarela J; Stenbäck F; Risteli J; Kauppila A; Risteli L
Am J Pathol; 1996 Feb; 148(2):539-48. PubMed ID: 8579116
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of HLA-DR antigen in serous ovarian tumors.
Tamiolakis D; Kotini A; Venizelos J; Jivannakis T; Simopoulos C; Papadopoulos N
Clin Exp Med; 2003 Sep; 3(2):113-8. PubMed ID: 14598186
[TBL] [Abstract][Full Text] [Related]
11. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
12. [Sharing antigenic determinant of colon carcinoma between serous and mucinous tumors of the ovary].
Liu MP; Lu ZT; Chen W
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):398-400, 444. PubMed ID: 7528120
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of laminin-5 in serous adenocarcinomas of the ovary.
Kohlberger P; Muller-Klingspor V; Heinzl H; Obermair A; Breitenecker G; Leodolter S
Anticancer Res; 2002; 22(6B):3541-4. PubMed ID: 12552953
[TBL] [Abstract][Full Text] [Related]
14. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
17. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
[TBL] [Abstract][Full Text] [Related]
18. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
Pisharodi LR; Bedrossian CW
Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
[TBL] [Abstract][Full Text] [Related]
19. The current status of surgical staging of ovarian serous borderline tumors.
Lin PS; Gershenson DM; Bevers MW; Lucas KR; Burke TW; Silva EG
Cancer; 1999 Feb; 85(4):905-11. PubMed ID: 10091769
[TBL] [Abstract][Full Text] [Related]
20. Neutral endopeptidase/CD10 expression in the stroma of epithelial ovarian carcinoma.
Khin EE; Kikkawa F; Ino K; Suzuki T; Shibata K; Kajiyama H; Tamakoshi K; Mizutani S
Int J Gynecol Pathol; 2003 Apr; 22(2):175-80. PubMed ID: 12649673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
